This page presents informaton about Covid-19 treatments and theirs eficacy, based on scientific reasearch and data.
Many of medicines and substances (herbs, spices) listed below are easily available and have been used for hundrets of years to treat infections.
The table below comes from https://c19early.com . Please, visit https://c19early.com for updated information.
Random effects meta-analysis of all studies combined (pooled effects, all stages). Treatments with ≤3 studies with distinct authors or with <50 control events are shown in grey. Pooled results across all stages and outcomes depend on the distribution of stages and outcomes tested – for example late stage treatment may be less effective and if the majority of studies are late stage this may obscure the efficacy of early treatment. Please see the specific stage and outcome analyses. Protocols typically combine multiple treatments which may be complementary and synergistic, and the SOC in studies often includes other treatments.
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Molnupiravir 89% 0.11 [0.01-0.90] 2 $700 964 very few trials/events Cost Studies Patients Improvement, RR [CI] Proxalutamide 84% 0.16 [0.12-0.22] 3 n/a 1,090 few trials/events Iota-carragee.. 80% 0.20 [0.04-0.89] 1 $1 394 very few trials/events Quercetin 72% 0.28 [0.07-1.06] 4 $5 736 very few trials/events Povidone-Iod.. 71% 0.29 [0.16-0.54] 7 $1 2,161 Nigella Sativa 67% 0.33 [0.21-0.52] 4 $5 1,291 few trials/events Sotrovimab 67% 0.33 [0.01-8.16] 1 $2,100 583 very few trials/events Ivermectin 65% 0.35 [0.27-0.43] 63 $1 47,461 Casirivimab/i.. 64% 0.36 [0.16-0.78] 7 $2,100 24,409 Melatonin 64% 0.36 [0.22-0.58] 11 $1 13,517 Fluvoxamine 63% 0.37 [0.09-1.47] 3 $4 1,749 few trials/events Curcumin 59% 0.41 [0.24-0.70] 9 $5 867 few trials/events Bamlanivimab 59% 0.41 [0.23-0.74] 7 $1,250 9,136 Vitamin A 55% 0.45 [0.18-1.10] 4 $2 636 few trials/events Nitazoxanide 55% 0.45 [0.15-1.35] 6 $4 1,464 Zinc 51% 0.49 [0.38-0.62] 17 $1 34,906 Budesonide 45% 0.55 [0.31-0.98] 3 $4 8,751 few trials/events Bromhexine 45% 0.55 [0.40-0.77] 5 $5 291 few trials/events Vitamin D 39% 0.61 [0.54-0.69] 46 $1 50,552 Favipiravir 37% 0.63 [0.48-0.81] 14 $20 3,068 Colchicine 31% 0.69 [0.54-0.88] 12 $1 17,762 Hydroxychloro.. 25% 0.75 [0.71-0.79] 294 $1 412,766 Probiotics 20% 0.80 [0.69-0.93] 12 $5 1,721 Aspirin 20% 0.80 [0.69-0.94] 20 $1 65,401 Remdesivir 19% 0.81 [0.73-0.89] 24 $3,120 97,505 Metformin 15% 0.85 [0.73-0.99] 7 $10 7,360 Vitamin C 11% 0.89 [0.78-1.01] 23 $1 15,499 Conv. Plasma -1% 1.01 [0.90-1.13] 13 $5,000 14,426 All studies combined (pooled effects, all stages) c19early.com Oct 20, 2021 Favors treatment Favors control
Random effects meta-analysis of
all studies combined (pooled effects, all stages). Treatments with ≤3
studies with distinct authors or with
<50 control events are shown in grey.
Pooled results across all stages and outcomes depend on the distribution of
stages and outcomes tested – for example late stage treatment may be less
effective and if the majority of studies are late stage this may obscure the
efficacy of early treatment. Please see the specific stage and outcome
analyses.
Protocols typically combine multiple treatments which may be complementary and
synergistic, and the SOC in studies often includes other treatments.
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fluvoxamine 89% 0.11 [0.01-0.85] 2 $4 277 very few trials/events Cost Studies Patients Improvement, RR [CI] Molnupiravir 89% 0.11 [0.01-0.90] 2 $700 964 very few trials/events Nigella Sativa 84% 0.16 [0.05-0.48] 3 $5 915 few trials/events Budesonide 82% 0.18 [0.04-0.79] 1 $4 146 very few trials/events Vitamin D 81% 0.19 [0.10-0.35] 6 $1 912 few trials/events Povidone-Iod.. 81% 0.19 [0.10-0.37] 6 $1 807 few trials/events Bromhexine 79% 0.21 [0.06-0.72] 2 $5 96 very few trials/events Vitamin A 79% 0.21 [0.07-0.61] 2 $2 240 very few trials/events Quercetin 79% 0.21 [0.02-1.82] 2 $5 194 very few trials/events Melatonin 78% 0.22 [0.06-0.75] 2 $1 91 very few trials/events Bamlanivimab 76% 0.24 [0.12-0.50] 4 $1,250 7,389 Zinc 75% 0.25 [0.04-1.71] 3 $1 982 very few trials/events Proxalutamide 73% 0.27 [0.03-2.39] 2 n/a 445 very few trials/events Curcumin 71% 0.29 [0.11-0.74] 6 $5 707 few trials/events Casirivimab/i.. 67% 0.33 [0.14-0.77] 4 $2,100 12,710 few trials/events Sotrovimab 67% 0.33 [0.01-8.16] 1 $2,100 583 very few trials/events Ivermectin 66% 0.34 [0.24-0.48] 28 $1 26,458 Hydroxychloro.. 64% 0.36 [0.29-0.46] 32 $1 54,621 Nitazoxanide 49% 0.51 [0.13-1.95] 5 $4 1,414 few trials/events Favipiravir 48% 0.52 [0.36-0.76] 4 $20 410 very few trials/events Vitamin C 46% 0.54 [0.19-1.51] 2 $1 208 very few trials/events Probiotics 34% 0.66 [0.55-0.80] 2 $5 323 few trials/events Metformin -15% 1.15 [0.73-1.83] 1 $10 423 very few trials/events Conv. Plasma -93% 1.93 [0.47-7.87] 3 $5,000 716 very few trials/events Early treatment studies (pooled effects) c19early.com Oct 20, 2021 Favors treatment Favors control
Random effects meta-analysis of
early treatment studies (pooled effects). Treatments with ≤3
studies with distinct authors or with
<50 control events are shown in grey.
Pooled results across all outcomes are affected by the distribution of
outcomes tested, please see detail pages for specific outcome analysis.
Protocols typically combine multiple treatments which may be complementary and
synergistic, and the SOC in studies often includes other treatments.
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Molnupiravir 89% 0.11 [0.01-0.90] 2 $700 964 very few trials/events Cost Studies Patients Improvement, RR [CI] Povidone-Iod.. 88% 0.12 [0.03-0.50] 1 $1 606 very few trials/events Nigella Sativa 87% 0.13 [0.04-0.49] 2 $5 732 few trials/events Bromhexine 87% 0.13 [0.01-1.23] 2 $5 178 very few trials/events Proxalutamide 84% 0.16 [0.12-0.22] 3 n/a 1,090 few trials/events Melatonin 79% 0.21 [0.08-0.56] 4 $1 1,650 Curcumin 70% 0.30 [0.14-0.64] 4 $5 434 Casirivimab/i.. 68% 0.32 [0.05-1.90] 3 $2,100 19,616 few trials/events Sotrovimab 67% 0.33 [0.01-8.16] 1 $2,100 583 very few trials/events Nitazoxanide 60% 0.40 [0.10-1.58] 3 $4 923 very few trials/events Probiotics 59% 0.41 [0.23-0.72] 4 $5 539 few trials/events Bamlanivimab 57% 0.43 [0.11-1.68] 4 $1,250 7,566 Ivermectin 55% 0.45 [0.33-0.62] 25 $1 34,963 Vitamin D 51% 0.49 [0.37-0.66] 28 $1 12,116 Quercetin 46% 0.54 [0.12-2.40] 3 $5 623 very few trials/events Vitamin A 42% 0.58 [0.07-4.59] 2 $2 207 few trials/events Zinc 41% 0.59 [0.47-0.75] 9 $1 10,298 Colchicine 40% 0.60 [0.42-0.86] 10 $1 17,373 Budesonide 39% 0.61 [0.22-1.67] 1 $4 1,586 very few trials/events Fluvoxamine 29% 0.71 [0.38-1.30] 1 $4 1,472 very few trials/events Hydroxychloro.. 22% 0.78 [0.73-0.83] 182 $1 291,163 Aspirin 20% 0.80 [0.68-0.94] 18 $1 54,857 Remdesivir 19% 0.81 [0.73-0.89] 23 $3,120 97,363 Vitamin C 19% 0.81 [0.66-0.99] 15 $1 14,063 Metformin 17% 0.83 [0.71-0.97] 6 $10 6,937 Favipiravir 8% 0.92 [0.60-1.41] 5 $20 2,119 Conv. Plasma -1% 1.01 [0.90-1.13] 13 $5,000 14,426 All mortality results (all stages) c19early.com Oct 20, 2021 Favors treatment Favors control
Random effects meta-analysis of
all mortality results (all stages). Treatments with ≤3
studies with distinct authors or with
<25 control events are shown in grey.
Pooled results across all stages depend on the distribution of stages tested –
for example late stage treatment may be less effective and if the majority of
studies are late stage this may obscure the efficacy of early treatment. Please
see the specific stage analyses.
Protocols typically combine multiple treatments which may be complementary and
synergistic, and the SOC in studies often includes other treatments.
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bromhexine 91% 0.09 [0.01-1.59] 1 $5 78 very few trials/events Cost Studies Patients Improvement, RR [CI] Molnupiravir 89% 0.11 [0.01-0.90] 2 $700 964 very few trials/events Casirivimab/i.. 89% 0.11 [0.00-3.00] 2 $2,100 9,831 few trials/events Povidone-Iod.. 88% 0.12 [0.03-0.50] 1 $1 606 very few trials/events Nigella Sativa 87% 0.13 [0.04-0.49] 2 $5 732 few trials/events Vitamin A 86% 0.14 [0.03-0.61] 1 $2 140 very few trials/events Bamlanivimab 85% 0.15 [0.03-0.77] 2 $1,250 6,784 few trials/events Curcumin 84% 0.16 [0.04-0.61] 2 $5 314 few trials/events Zinc 79% 0.21 [0.03-1.47] 1 $1 518 very few trials/events Quercetin 79% 0.21 [0.02-1.82] 2 $5 194 very few trials/events Vitamin D 79% 0.21 [0.12-0.39] 4 $1 514 few trials/events Hydroxychloro.. 75% 0.25 [0.16-0.40] 13 $1 50,628 Proxalutamide 73% 0.27 [0.03-2.39] 2 n/a 445 very few trials/events Sotrovimab 67% 0.33 [0.01-8.16] 1 $2,100 583 very few trials/events Ivermectin 50% 0.50 [0.37-0.67] 9 $1 24,282 Favipiravir 45% 0.55 [0.05-5.81] 1 $20 92 very few trials/events Nitazoxanide 41% 0.59 [0.02-13.8] 2 $4 873 very few trials/events Conv. Plasma -93% 1.93 [0.47-7.87] 3 $5,000 716 very few trials/events Early treatment mortality results c19early.com Oct 20, 2021 Favors treatment Favors control
Random effects meta-analysis of
early treatment mortality results. Treatments with ≤3
studies with distinct authors or with
<25 control events are shown in grey.
Protocols typically combine multiple treatments which may be complementary and
synergistic, and the SOC in studies often includes other treatments.